Ondine Biomedical (FRA:VF5) Cash per Share: €0.01 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VF5 Ondine Biomedical Inc FRA:VF5
37 GF Score
Price €0.12
GF Value €0.09
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Cash per Share?

Ondine Biomedical FRA:VF5 -0.85% 37 Cash per Share is €0.01 as of Dec. 2025. GuruFocus rates FRA:VF5 with a GF Score™ of 37/100 and a GF Value™ of €0.09 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Ondine Biomedical's Cash per Share for the quarter that ended in Dec. 2025 was €0.01.

Ondine Biomedical  (FRA:VF5) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Ondine Biomedical Cash per Share Related Terms

Ondine Biomedical Cash per Share Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Cash per Share Chart

Ondine Biomedical Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.05 0.01 0.02 0.01

Ondine Biomedical Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.02 0.01 0.01
FRA:VF5
37GF Score
Ondine Biomedical Inc FRA:VF5
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Ondine Biomedical's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=6.541/518.37
=0.01

Ondine Biomedical's Cash per Share for the quarter that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=6.541/518.37
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of €0.01 mean?
Ondine Biomedical (FRA:VF5) has a Cash per Share of €0.01 as of Dec. 2025. Cash per share is the per-share value of a company's available cash. View historical data for Ondine Biomedical and its competitors.
Is Ondine Biomedical's Cash per Share too high?
Ondine Biomedical's current Cash per Share is €0.01. Overall, Ondine Biomedical has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Cash per Share compare to VRTX and REGN?
Ondine Biomedical's Cash per Share of €0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Ondine Biomedical and its competitors. Ondine Biomedical's current Cash per Share is €0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.12 — trading 30% above its estimated fair value. The current Cash per Share is €0.01. Ondine Biomedical's overall GF Score™ is 37/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Cash per Share is €0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of €0.12 is trading 30% above its estimated GF Value™ of €0.09. GuruFocus considers Ondine Biomedical to be Modestly Overvalued.

Key valuation signals for FRA:VF5:

  • Cash per Share: €0.01
  • GF Value™: €0.09 vs. price of €0.12 (30% above fair value)
  • GF Score™: 37/100 with 9 warning signs

No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBIMF:USAOBI:UK
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
37GF Score

Get the complete analysis for FRA:VF5

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.09
GF Value